94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study

{"title":"94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study","authors":"D. Ziogas , H. Linardou , A. Charpidou , A. Koumarianou , G. Mountzios , P. Kosmidis , C. Christodoulou , D. Mavroudis , A.N. Christopoulou , I. Korantzis , S. Baka , M. Vaslamatzis , I. Athanasiadis , A. Koutras , D. Mauri , A. Kotsakis , A. Visvikis , F. Spanoudi , T. Tsichritzis , K. Syrigos","doi":"10.1016/j.iotech.2024.100837","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100837"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}